Search results
2 mar 2021 · We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections,...
20 sty 2024 · Cervical cancer rates are rising among women in their 30s and early 40s, a new report finds. However, among women in their early 20s who have benefitted from the HPV vaccine, cervical cancer...
19 lip 2023 · Women with human immunodeficiency virus (HIV) (WWH) are at increased risk of human papillomavirus (HPV) infection and cervical cancer as compared to HIV-negative individuals. HPV vaccination remains a priority in regions with a high burden of cervical cancer and high HIV prevalence.
Among people living with HIV (PLHIV), who were seronegative for the vaccine type HPV infection prior to vaccination, seroconversion rates were high 28 weeks after receiving the first vaccine dose: more than 94% of PLHIV seroconverted for HPV-16/18 across three vaccines.
20 lut 2023 · One-dose human papillomavirus (HPV) vaccination schedules are now recommended by the WHO. We explore HPV vaccination challenges and research needs for women living with HIV.
By serological antibody testing in a recent vaccine immunogenicity trial among HIV-infected women, only 4% of the participants had evidence of prior exposure to all 4 vaccine associated HPV types, either due to lack of prior HPV exposure or due to loss of serum HPV antibodies.
11 kwi 2022 · SAGE’s review concluded that a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules. This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls.
